VR Logo

Verve Therapeutics Inc. (VERV) download report


Healthcare | Biotechnology & Pharma Research

Verve Therapeutics Inc. (VERV) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases.

IPO Date: 17-Jun-2021

Co-Founder, CEO & Director: Dr. Sekar Kathiresan M.D.

Co-Founder & Scientific Advisory Board Member: Dr. Anthony Philippakis M.D., Ph.D.

Listing: NASDAQ: VERV

Country: United States

Headquarters: Cambridge, MA

Website: https://www.vervetx.com

Key Facts

Market cap: $686.13 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-137.22 Mln

Cash: $323.30 Mln

Total Debt: $1.43 Mln

Insider's Holding: 35.39%

Liquidity: Low

52 Week range: $10.70 - 78.00

Shares outstanding: 48,661,400

Stock Performance

Time Period Verve Therapeutics (VERV) S&P BSE Sensex S&P Small-Cap 600
YTD-54.16-9.49-17.79
1 month21.32-2.87-2.72
3 months-24.96-8.59-12.17
1 Year-54.560.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022